Johnson & Johnson $JNJ Stock: Pictet Asset Management Holding SA Raises Stake

Pictet Asset Management Holding SA boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,864,710 shares of the company’s stock after purchasing an additional 11,452 shares during the period. Pictet Asset Management Holding SA owned about 0.08% of Johnson & Johnson worth $493,666,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Verus Capital Partners LLC increased its position in shares of Johnson & Johnson by 6.0% during the third quarter. Verus Capital Partners LLC now owns 8,026 shares of the company’s stock worth $2,125,000 after acquiring an additional 456 shares during the period. AlphaCentric Advisors LLC raised its stake in shares of Johnson & Johnson by 11.4% during the 3rd quarter. AlphaCentric Advisors LLC now owns 1,549 shares of the company’s stock worth $410,000 after acquiring an additional 158 shares in the last quarter. Tennessee Valley Asset Management Partners boosted its stake in Johnson & Johnson by 1.5% in the third quarter. Tennessee Valley Asset Management Partners now owns 3,211 shares of the company’s stock valued at $850,000 after acquiring an additional 48 shares in the last quarter. Parallel Advisors LLC lifted its holdings in shares of Johnson & Johnson by 2.6% during the 3rd quarter. Parallel Advisors LLC now owns 85,192 shares of the company’s stock valued at $22,554,000 after purchasing an additional 2,157 shares during the last quarter. Finally, Prudent Man Investment Management Inc. increased its holdings in shares of Johnson & Johnson by 68.3% during the third quarter. Prudent Man Investment Management Inc. now owns 589 shares of the company’s stock valued at $156,000 after acquiring an additional 239 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 1.4%

Shares of Johnson & Johnson stock opened at $276.14 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The company has a 50 day moving average of $265.91 and a 200 day moving average of $248.30. The company has a market capitalization of $664.76 billion, a P/E ratio of 41.84, a P/E/G ratio of 2.73 and a beta of 0.22. Johnson & Johnson has a 52-week low of $185.12 and a 52-week high of $282.02.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. Johnson & Johnson’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, research analysts forecast that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 81.21%.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

JNJ has been the subject of a number of research reports. Argus set a $300.00 price target on Johnson & Johnson in a research report on Wednesday, July 29th. Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. UBS Group set a $270.00 price target on Johnson & Johnson in a report on Wednesday, October 14th. Erste Group Bank lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Finally, Wells Fargo & Company boosted their price target on shares of Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research note on Friday, October 16th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $275.92.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for certain adults with recurrent or metastatic head and neck cancer after prior platinum chemotherapy and immunotherapy. J&J says the treatment is the first new option in this setting in a decade; trial data showed a 42% response rate. The approval extends the drug’s use beyond lung cancer and could broaden its commercial opportunity, though the indication is limited and accelerated approval may require confirmatory evidence. FDA approval announcement
• Positive Sentiment: J&J’s Innovative Medicine division grew third-quarter sales 7.7% to $16.76 billion, with established blockbusters and new launches more than offsetting generic competition. Continued growth despite patent-related headwinds supports the business outlook. Innovative Medicine sales report
• Neutral Sentiment: J&J was included in an article highlighting companies with a history of dividend increases and strong balance sheets. This reinforces its income-investor appeal, but the article does not identify a new company-specific dividend announcement. Dividend raisers article
• Negative Sentiment: Pomerantz LLP announced it is investigating potential claims on behalf of J&J investors. The notice does not provide details of the claims, but the investigation could add legal and reputational uncertainty. Investor investigation announcement

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.